MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10840-026-02263-4

Медицинская библиотека · Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026

Outcomes of individual DOACs vs. VKAs in AF patients with frailty: a systematic review and meta-analysis.

Quevillon Travis, Chiu Justin, Amlogu Peter, Michael Faith, McIntyre William F, Parkash Ratika, Andrade Jason G, Jackevicius Cynthia A, Healey Jeff S, Ko Dennis T, Shurrab Mohammed

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Atrial fibrillation (AF) patients with frailty represent a particularly complex and medically vulnerable population. These patients are simultaneously at increased risk for ischemic stroke and bleeding complications, complicating decisions around anticoagulant therapy. This systematic review and meta-analysis sought to evaluate the comparative safety and efficacy of individual direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in AF patients with frailty.

METHODS

We systematically searched MEDLINE, Embase, and CENTRAL for studies published to July 2, 2024. Included studies compared individual DOACs to VKAs in AF patients with frailty. Outcomes were stroke/systemic embolism (SSE) and major bleeding. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using a random-effects model.

RESULTS

A total of six studies (one randomized trial and five cohort studies) met inclusion criteria, encompassing 272,545 patients (108,666 treated with VKAs and 163,879 with DOACs). Among DOAC-treated patients, 62,961 were treated with apixaban, 21,954 with dabigatran, 10,813 with edoxaban and 68,151 with rivaroxaban. Of the six included studies, four reported stroke or systemic embolism in patients taking apixaban, five reported this outcome for dabigatran, four for edoxaban, and five for rivaroxaban. Four studies reported major bleeding in patients taking apixaban, five reported major bleeding for dabigatran, four for edoxaban, and five for rivaroxaban. Among DOACs, apixaban was associated with significant reductions in SSE (OR 0.56, 95% CI 0.33–0.95, p = 0.03) and major bleeding (OR 0.52, 95% CI 0.29–0.95, p = 0.03) compared with VKAs. Other DOACs demonstrated numerical trends toward reduced SSE and major bleeding but did not reach statistical significance.

CONCLUSIONS

These findings suggest that apixaban is associated with a more favorable safety and efficacy profile than VKAs in AF patients with frailty. This analysis supports the preferential use of apixaban in this population, while highlighting the need for individualized risk assessment and clinical judgment.

Для цитирования: Quevillon Travis, Chiu Justin, Amlogu Peter, Michael Faith, McIntyre William F, Parkash Ratika, Andrade Jason G, Jackevicius Cynthia A, Healey Jeff S, Ko Dennis T, Shurrab Mohammed. Outcomes of individual DOACs vs. VKAs in AF patients with frailty: a systematic review and meta-analysis.. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing. 2026. DOI: 10.1007/s10840-026-02263-4.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.